Progenics Pharmaceuticals (PGNX) Shares are Up 7.35%

Progenics Pharmaceuticals (PGNX) : Traders are bullish on Progenics Pharmaceuticals (PGNX) as it has outperformed the S&P 500 by a wide margin of 12.02% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.89%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.35% in the last 1 week, and is up 14.81% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Progenics Pharmaceuticals (NASDAQ:PGNX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $6.04 and $5.95 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.38. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.28, notching a gain of 5.90% for the day. The total traded volume was 3,639,955 . The stock had closed at $5.93 on the previous day.

The stock has recorded a 20-day Moving Average of 11.72% and the 50-Day Moving Average is 23.79%. Progenics Pharmaceuticals, Inc. is up 24.6% in the last 3-month period. Year-to-Date the stock performance stands at 2.45%.

Progenics Pharmaceuticals (PGNX) : 2 investment research analysts covering Progenics Pharmaceuticals (PGNX) have an average price target of $11.5 for the near short term. The highest target price given by the Brokerage Firm to the stock is $14 and the lowest target is $9 for the short term. Analysts expect the variance to be within $3.54 of the average price.


Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.